Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...

Hearing plea of couple whose research work had been stolen, Bombay HC in 2023 ruled that ‘property’ under Section 15A of ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030.

More enterprises will prefer hybrid infrastructure solutions over time, and IBM is positioned to meet this need. IBM carries a sizable debt load, measuring $55 billion as of December 2024. However, ...

Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy ...

Net income of $13.7 million, or $0.71 per diluted share, for the three months ended December 31, 2024 compared to net loss of $7.9 million, or $0.41 per diluted share, for the three months ended Septe ...

India's efforts have also been recognised globally. The country now ranks 39th among 133 economies in the Global Innovation Index 2024, a sharp improvement from 81st in 2015. It also leads among lower ...

Completes exit from banking-as-a-service depository operations Performance reflects sequential improvement in deposit growth, noninterest expense reduction, and nonperforming ...